AKRX(.25)~ 34 pending ANDAs represent a total market opportunity of ~$5.6B with significant diversification by dosage form http://investors.akorn.com/static-files/04aa0f33-1acf-4b9a-a59e-bb6a80a08fbc ------------------------------------------- AKRX~ German Drug Maker Fresenius offered $34 per share to buyout. Deal dropped later. AKRX is a lot cheap now. https://drugstorenews.com/otc/fresenius-kabi-acquire-akorn-b ------------------------------------------------------------------- AKRX has lots of FDA approved drugs.. https://www.akorn.com/about_timeline.php ------------------------------------------------ AKRX has over 150 generic drugs https://www.akorn.com/prod_list_all.php